✦ Foundayo & the Oral EraNarrow moat

The obesity market's biggest barrier was never efficacy — it was needles, cold chains and supply. Foundayo removes all three: a once-daily small-molecule GLP-1, approved April 1, 2026 on the ATTAIN Phase 3 program, that can be taken any time without food or water restrictions — unlike Novo's oral semaglutide, which demands an empty stomach — and that ships from ordinary factories rather than sterile fill-finish lines¹. Lilly priced for volume: $25 a month with a commercial savings card, $149 self-pay at the entry dose, $50 for Medicare members from July, with LillyDirect home delivery from launch week².

The strategic point is cannibalization on Lilly's terms: at 12.4% average weight loss, the pill trails Zepbound's injectable numbers — deliberately acceptable, because the patients it recruits are the tens of millions who would never inject, and every one who starts oral stays inside Lilly's franchise rather than a rival's. Watch three things: the prescription curve against Novo's oral, gross-to-net pricing as insurers negotiate, and persistence — pills are easier to start and easier to quit, and the franchise's economics depend on refills, not first fills.